Cue Biopharma grants CFO options and RSUs

Cue Biopharma, Inc. granted Chief Financial Officer James M. Ahlers two equity awards on July 30, 2026: a stock option for 51,000 shares of common stock at an exercise price of $30.40 per share, expiring July 30, 2036, and 25,500 restricted stock units.

Rhea-AI Filing Summary

Cue Biopharma, Inc. granted Chief Financial Officer James M. Ahlers two equity awards on July 30, 2026: a stock option for 51,000 shares of common stock at an exercise price of $30.40 per share, expiring July 30, 2036, and 25,500 restricted stock units. Both the option and RSUs vest in equal quarterly installments over four years from July 30, 2026, subject to his continued service with the company through each vesting date.

Insider Trade Summary

Grant/Award: 76,500 shares

Grant/Award 2 txns

Insider Ahlers James M

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F2	51,000	$0.00	$0.00
Grant/Award	Common Stock F1	25,500	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 51,000 contracts (Direct); Common Stock — 25,500 shares (Direct)

Footnotes (2)

1. F1. Represents the grant of restricted stock units ("RSUs"). The shares subject to the RSU vest in equal quarterly installments over four years from July 30, 2026, subject to the reporting person's continued service with the issuer through each vest date.
2. F2. The stock option becomes exercisable in equal quarterly installments over four years from July 30, 2026, subject to the reporting person's continued service with the issuer through each vest date.

Key Figures

Stock options granted: 51,000 shares Option exercise price: $30.40 per share Option expiration date: July 30, 2036 +2 more

5 metrics

Stock options granted 51,000 shares Stock option for common stock granted to CFO on July 30, 2026

Option exercise price $30.40 per share Exercise price for the 51,000-share stock option grant

Option expiration date July 30, 2036 Expiration of CFO stock option granted on July 30, 2026

Restricted stock units granted 25,500 shares RSUs granted to CFO on July 30, 2026

Vesting period 4 years Both option and RSUs vest quarterly over four years from July 30, 2026

Key Terms

restricted stock units ("RSUs"), stock option, vest in equal quarterly installments, exercisable in equal quarterly installments

4 terms

restricted stock units ("RSUs") financial

"Represents the grant of restricted stock units ("RSUs")."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

stock option financial

"The stock option becomes exercisable in equal quarterly installments"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

vest in equal quarterly installments financial

"The shares subject to the RSU vest in equal quarterly installments"

exercisable in equal quarterly installments financial

"The stock option becomes exercisable in equal quarterly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Cue Biopharma (CUE) grant its CFO on July 30, 2026?

Cue Biopharma granted CFO James M. Ahlers a stock option for 51,000 common shares at $30.40 per share, expiring July 30, 2036, plus 25,500 restricted stock units. Both awards vest quarterly over four years from July 30, 2026, contingent on continued service.

What is the vesting schedule for the Cue Biopharma (CUE) CFO’s new stock option and RSUs?

Both the 51,000-share stock option and 25,500 RSUs vest in equal quarterly installments over four years starting July 30, 2026. Each vesting tranche requires the CFO to continue serving Cue Biopharma through the applicable vesting date.

What are the key terms of the Cue Biopharma (CUE) CFO’s 51,000-share stock option grant?

The CFO received a stock option covering 51,000 Cue Biopharma common shares at an exercise price of $30.40 per share. The option becomes exercisable in equal quarterly installments over four years from July 30, 2026, and expires on July 30, 2036.

Did the Cue Biopharma (CUE) CFO buy or sell any existing shares in this Form 4?

No purchases or sales of existing shares are reported. The Form 4 reflects only equity awards granted by Cue Biopharma: a 51,000-share stock option and 25,500 restricted stock units, both subject to multi-year quarterly vesting and continued service conditions.

How many Cue Biopharma (CUE) shares are covered by the CFO’s awards after this Form 4?

Following these grants, the CFO holds a stock option covering 51,000 shares and 25,500 shares underlying restricted stock units. These amounts reflect the awards granted on July 30, 2026, and will vest over four years as service conditions are met.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/03/2026 - 04:19 PM Accepted by SEC EDGAR 08/03/2026 - 04:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ahlers James M

(Last) (First) (Middle)

C/O CUE BIOPHARMA, INC.

40 GUEST STREET

(Street)

BOSTON MASSACHUSETTS 02135

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cue Biopharma, Inc. [ CUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/30/2026		A		25,500(1)	A	$0	25,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$30.4	07/30/2026		A		51,000		(2)	07/30/2036	Common Stock	51,000	$0	51,000	D

Explanation of Responses:

1. Represents the grant of restricted stock units ("RSUs"). The shares subject to the RSU vest in equal quarterly installments over four years from July 30, 2026, subject to the reporting person's continued service with the issuer through each vest date.

2. The stock option becomes exercisable in equal quarterly installments over four years from July 30, 2026, subject to the reporting person's continued service with the issuer through each vest date.

	/s/ Michael Meluzio, Attorney-in-Fact	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)